Back to search results
NCT06967467

Allergy Delabeling in Antibiotic Stewardship - Evaluations

Enrolling by Invitation
Not specifiedAges 18+Observational
Abramson Cancer Center at Penn Medicine
~80 participants
Updated 2026-06-05 on ClinicalTrials.gov
What's tested:Semi-structured interviewSurveyEthnographic observation

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Feasibility of Implementation
Measured over From baseline Month 1 to Month 36
+1 more outcome measured

Conditions

Beta Lactam Allergy in Patients With a Hematologic Malignancy

Explore related trials

Beta Lactam AllergyMalignant neoplasm of lymphoid, hematopoietic and/or related tissue

NCT06967467

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvaniano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

a diagnosis of a hematologic malignancy (lymphoma, leukemia, myeloma)
a prior label applied to their medical record to indicate a beta lactam allergy
hospitalized as an inpatient to an oncology service at the time the study is conducted
member of the primary inpatient care team

Exclusion

no exclusions

What this trial measures

  • Feasibility of ImplementationFrom baseline Month 1 to Month 36

    Feasibility of implementation among clinicians and patients measured by questionnaire. Items are adapted from the validated Feasibility of Implementation Measure (FIM) and are rated on a 5-point Likert scale ranging from 1 to 5, with 1 indicating "Completely disagree" and 5 indicating "Completely agree." Higher scores indicate better feasibility. The items are analyzed individually and not summed to a total score.

  • Acceptability of ImplementationFrom baseline Month 1 to Month 36

    Acceptability of implementation among clinicians and patients measured by questionnaire. Items are adapted from the validated Acceptability of Implementation Measure (AIM) and are rated on a 5-point Likert scale ranging from 1 to 5, with 1 indicating "Completely disagree" and 5 indicating "Completely agree." Higher scores indicate better acceptability. The items are analyzed individually and not summed to a total score.